

# Under the auspices of:









with international participation

Dear Colleagues,

cordially welcome you to the 10<sup>th</sup> Symposium on "Cardiovascular Disease and Renal Dysfunction 2018" with international participation, which is held in Athens, at the Eugenides Foundation, on January 19-20, 2018.

The Symposium "Cardiovascular Disease and Renal Dysfunction 2018" is an effort to enhance the interchange of emerging new information on pathophysiological and clinical interrelationships between kidneys, the heart and the vasculature.

During the Symposium we will have the opportunity to attend Sessions with the participation of world experts, who are pioneers in the field of cardiovascular research. Through Round Table discussions and Debates, the Symposium offers an outstanding Scientific Program, featuring both state-of-the-art knowledge and innovative approaches of the patient with renal impairment and cardiovascular disease.

We anticipate that this Symposium will be valuable in terms of both everyday clinical practice and advanced research.

We look forward to providing you with the famous Greek hospitality, in what promises to be an exciting scientific event.

Sincerely,

**Dimitrios Tousoulis** 

Chairman of the Organizing Committee Professor of Cardiology Director, 1st Department of Cardiology Athens University Medical School "Hippokration" Hospital, Athens, Greece **Konstantinos Tsioufis** 

Co-Chairman of the Organizing Committee
Associate Professor of Cardiology
1st Department of Cardiology
Athens University Medical School
"Hippokration" Hospital, Athens, Greece
President of H.C.S.
President of E.S.H.

with international participation

# **Organizing Committee**

Symposium Chairman: **Dimitrios Tousoulis** 

Professor of Cardiology, Director of the 1st Department of Cardiology, Athens University Medical School,

"Hippokration" Hospital, Athens, Greece

Symposium Co-Chairman: Konstantinos Tsioufis

Associate Professor of Cardiology, 1st Department of Cardiology, Athens University Medical School, "Hippokration" Hospital, Athens, Greece

President of H.C.S. President of E.S.H.

# **International Invited Faculty**

**George Bakris** Professor of Medicine

University of Chicago Hospitals

Director, ASH Comprehensive Hypertension Center University of Chicago Medicine, Chicago IL, USA

**Gérard London** Professor of Nephrology

Nephrology Department Hospital Center Manhès,

Fleury Mérogis, Essonne, FRANCE

Vassilios Papadimitriou Professor of Medicine (Cardiology)

Georgetown University

Director Interventional Hypertension and Vascular

Medicine Program

VA Medical Center, Washington DC, USA

**Josep Redon** Professor of Medicine

University of Valencia, SPAIN

with international participation

# **General Information**

### **Scientific Secretariat**

# 1<sup>st</sup> Department of Cardiology, Athens University Medical School "Hippokration" Hospital

114, Vas. Sofias Ave., GR 115 27 Athens, Greece Tel.: +30 213 20 88 099, Fax: +30 213 20 88 676

E-mail: ktsioufis@hippocratio.gr, Web-site: www.cardiorenal2018.gr

# **Organizing Secretariat**

### THE MASTERMIND GROUP

26, Marathonomahon Str., GR 151 24 Maroussi, Greece Tel.: +30 210 68 27 405, Fax: +30 210 68 27 409 E-mail: mbriki@tmg.gr, Web-site: www.tmg.gr

# Symposium Date

January 19-20, 2018

# Symposium Venue

# **Eugenides Foundation**

387, Syggrou Ave., GR 175 64 Athens, Greece Tel.: +30 210 94 69 600, Fax: +30 210 94 17 372

# Registration

Registration to the Symposium is free.

# Official Language

The official languages of the Symposium are greek and english.

# **Certificate of Attendance**

All registered participants will receive a Certificate of Attendance from the Symposium Secretariat, after the end of the Scientific Program.

### Accreditation

The Symposium is accredited by the Greek Medical Association for **11 hours of External CME Credits**.

# Workshop

# Diabetes mellitus in the era of integrated cardiovascular and renal care

# Friday, January 19, 2018

15.00-15.30	Registrations
15.30-17.00	Debates
	Chairmen: G. Dimitriadis, N. Tentolouris, T. Makris
	1. Is diabetes mellitus an equivalent of coronary artery disease?
15.30-15.40	Pro: E. Chatziaggelaki
15.40-15.50	Contra: I. Ioannidis
	2. Is Metformin the ideal drug for first line therapy?
15.50-16.00	Pro: A. Raptis
16.00-16.10	Contra: A. Thanopoulou
	3. The target blood pressure should be<130/80mmHg?
16.10-16.20	Pro: C. Grassos
16.20-16.30	Contra: D. Papadopoulos
16.30-16.50	Comments:
	• E. Andrikou, M. Papavassiliou
	I. Kyriazis, M. Noutsou
4.6.50.4.7.00	• A. Pittaras, E. Triantafilidi
16.50-17.00	Discussion with the audience
17.00-17.30	Satellite Lecture BOEHRINGER INGELHEIM
17.30-17.45	Intermission - Coffee break
17.45-18.15	Satellite Lecture ASTRAZENECA

# Workshop

# Diabetes mellitus in the era of integrated cardiovascular and renal care

# Friday, January 19, 2018

18.15-19.30	Round Table: "Diabetic complications from A to Z"
	Chairmen: S. Pappas, K. Makrylakis, G. Katsimagklis
18.15-18.27	Diabetic neuropathy N. Papanas
18.28-18.40	Diabetic nephropathy V. Lambadiari
18.41-18.53	Diabetic myocardiopathy G. Siasos
18.54-19.06	Peripheral artery disease C. Vlachopoulos
19.07-19.19	Comments: M. Kalistratos, A. Lepouras, F. Lagiou, A. Synetos
19.20-19.30	Discussion with the audience
19.30-20.45	5 minutes presentations of best paper (s) in 2017 related to:
	K. Aggeli, A. Melidonis, A. Mitrakou
19.30-19.35	Cardiovascular effects of antidiabetic drugs  I. Elefteriadou
19.36-19.41	How to screen an asymptomatic diabetic patient for CAD  D. Konstantinidis
19.42-19.47	Arrhythmias in diabetic patient  A. Kordalis
19.48-20.03	Non alcoholic fatty liver disease in diabetes melitus A. Kasiakogias
20.04-20.09	Hypoglycemia and cardiovascular risk  O. Kaitozis
20.10-20.15	Revascularization of a diabetic patient  D. Syrseloudis
20.15-20.45	Comments-Discussion:
	• V. Katsi, K. Masoura
	• S. Galanakos, K. Kintis
	N. Magkas, K. Traxanas
	<ul><li>M. Divani, G. Karapati</li><li>A. Aggelis</li></ul>
	• A. Aggelis • D. Papoutsis
	· · · · · · · · · · · · · · · · · · ·

with international participation

08.25-08.30	Welcome address
	D. Tousoulis, Chairman of the Symposium
	K. Tsioufis, Co-Chairman of the Symposium
08.30-09.45	Round Table: "How to manage clinical cardiorenal cases"
	Chairmen: D. Alexopoulos, C. Pitsavos
08.30-08.42	A 75-years-old patient admitted for acute pulmonary edema and glomerular filtration rate <30 mL/min/1.73m <sup>2</sup> V. Bistola
08.43-08.55	A 52-years-old patient with history of heart failure admitted due to ascites and peripheral edema with deterioration of kidney function <b>G. Giannakoulas</b>
08.56-09.08	A 80-years-old diabetic lady with severe aortic valve stenosis admitted for syncope K. Toutouzas
09.08-09.20	A 54-years-old man with ischemic cardiomyopathy and 3 vessel disease E. Vavouranakis
09.20-09.32	Comments: M. Sonikian, N. Kaperonis, G. Latsios, N. Kafkas
09.33-09.44	Discussion with the audience
09.45-10.10	Lecture
	Chairman: <b>P. Pasadakis</b>
	Common problems for the cardiologist in the management of patients with chronic kidney disease  D. Goumenos
10.10-10.40	Satellite Lecture WINMEDICA
10.40-11.00	Intermission - Coffee break

with international participation

11.00-12.30	Special Session: "The Hellenic cardio-renal community meets the experts"
	Coordinators: D. Tousoulis, N. Zakopoulos, K. Tsioufis
11.00-11.15	The new ACC-AHA guidelines for hypertension <b>G. Bakris</b>
11.16-11.31	The debate about SPRINT: Why are we still arguing? V. Papademetriou
11.32-11.47	Acute decline in GFR after blood pressure treatment. What to do? <b>J. Redon</b>
11.48-12.03	Accelerated vascular aging G. London
12.04-12.15	Panelists: M. Doumas, A. Manolis, G. Stergiou, K. Thomopoulos
12.16-12.30	Discussion with the audience
12.30-13.00	Satellite Lecture BAYER & ELPEN
13.00-13.30	Satellite Lecture NOVARTIS
13.30-15.00	Round Table: "Antithrombotic therapy in patients with cardio renal disease: A puzzle to be solved"
	Chairmen: C. Karvounis, A. Spanos, V. Voudris
13.30-13.38	1. Antithrombotic therapy in a patient with atrial fibrillation and GFR<45 Dikoumarol must be our choice P. Dilaveris
13.39-13.47	NOAC is the preferable choice V. Vasilikos
13.48-13.56	2. Dual antiplatelet treatment after stenting in CAD and GFR <45 Aspirin and clopidogrel remains the gold standard D. Tziakas
13.57-14.05	Aspirin and ticagrelor is the preferable choice P. Davlouros
14.05-14.13	3. Antithrombotic strategy in a patient with ACS and AF Triple antithrombotic treatment remains our choice J. Kanakakis
14.14-14.22	NOAC and single antiplatelet treatment is the preferable choice <b>S. Patsilinakos</b>
14.23-14.45	Comments-Discussion:
	<ul><li>L. Poulimenos, E. Sanidas</li><li>P. Stougianos, S. Vaina</li><li>D. Tsiachris, J. Skiadas</li></ul>
14.46-15.00	Discussion with the audience

with international participation

15.00-15.30	Lunch Break
15.30-16.15	Debate: "How to best manage a patient with stable coronary artery disease and renal dysfunction"
	Chairmen: I. Kallikazaros, S. Foussas
15.30-15.38	Just manage risk factors and give drugs! C. Olympios
15.39-15.47	Just open the arteries! A. Androulakis
15.48-16.05	Surgeons' view: J. Chlorogiannis, V. Kotsis, N. Koumalos, D. Nikas, G. Pattakos
16.06-16.14	Discussion with the audience
16.15-17.20	Round Table: "Patient with cardio-renal disease and comorbidities. What the cardiologist should know in case of: " Chairmen: I. Bolletis, D. Boumbas, C. Stefanadis
16.15-16.27	Hepatic involvement  I. Koskinas
16.28-16.40	Exacerbation of COPD S. Loukidis
16.41-16.53	Rheumatic disorders  D. Vasilopoulos
16.54-17.06	Anemia L. Gianouli
17.07-17.20	Comments-Discussion: S. Kakouros, A. Avgeropoulou, K. Aznaouridis, E. Rentoukas
17.20-17.45	Intermission - Coffee break

with international participation

17.45-19.00	Round Table: "Hot issues in a cardiorenal patient explained by experts"
	Chairmen: F. Triposkiadis, A. Karabinis, Ant. Manolis
17.45-17.55	Pulmonary hypertension  I. Paraskevaidis
17.56-18.06	Large pericardial effusion G. Lazaros
18.07-18.17	Hyponatriemia-hyperkaliemia D. Vlachakos
18.18-18.28	Vitamin D deficiency  D. Petras
18.29-18.39	Proteinuria R. Kalaitzidis
18.40-18.59	Comments-Discussion: A. Kitsiou, I. Barbetseas, N. Afentakis, G. Psimenos, Th. Apostolou
19.00-20.15	Round Table: "Heart failure in the patient with renal disease: the double-edged sword"
	Chairmen: E. Iliodromitis, E. Tsiamis
19-00-19.12	Hemodialysis as therapeutic tool in 2018 P. Sarafidis
19.13-19.25	Inotropic therapy: Experts' opinion is still valuable  A. Trikas
19.26-19.38	CRT-ICD implantation K. Gatzoulis
19.39-19.51	Heart failure therapy: From the established to emerging therapies <b>D. Farmakis</b>
19.52-20.15	Comments-Discussion: A. Gouziouta, E. Oikonomou, S. Sideris, S. Marinaki
20.15	Conclusion K. Tsioufis

# Η διαφορά του Livazo®

Αποτεθεσματικός έθεγχος της LDL-C (έως - 47%) με μακροπρόθεσμη αύξηση και διατήρηση της HDL-C, ενώ φαίνεται να έχει ουδέτερη ή θετική επίδραση στο μεταβοθισμό της γθυκόζης1



CHORALEU TOY ARAMANET TWOY PROTOTOS: Insua. 1 mg Socia carachiquation is A territ quiete. Listos 2 mg Socia carachiquation is a territ quiete. Listos 4 mg Socia carachiquation is a territ quiete. Listos 4 mg Socia carachiquation is a territ quiete. Listos 5 mg Socia carachiquation is a territ quiete. Listos 4 mg Socia carachiquation is a territ quiete. Listos 5 mg Socia carachiquation is a territ quiete. Listos 5 mg Socia carachiquation is a territ quiete of the control of the cont

BIRADEPAGE: 1. American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care, 2016;39(suppl 1):51-5106. January 2016. 2. Kpritipio traupplacing particlolws outdooks on medical care in diabetes—2016. Diabetes Care, 2016;39(suppl 1):51-5106. January 2016. 2. Kpritipio traupplacing particlology, particlology. Research of the complete season of the complete season



# Διαχρονικές Θεραπευτικές Λύσεις Αξίας





irbesartan + HCTZ

**Tablets** F.C. Tablets 150/12.5mg • 300/12,5mg • 300/25mg



Πριν τη συνταγογράφηση, συμβουλευτείτε τις Π.Χ.Π. που είναι αναρτημένες στο www.sanofi.gr.